Charles Explorer logo
🇬🇧

Budesonid - nová naděje v léčbě IgA nefropatie : komentář

Publication at First Faculty of Medicine |
2017

This text is not available in the current language. Showing version "cs".Abstract

Komentář k: Fellström BC, Barratt J, Cook H, et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.

Lancet 2017;389:2117-2127.